Home
report store
congestive heart failure chf market

Congestive Heart Failure (CHF) - Market Insights, Epidemiology and Market Forecast– 2030

Published Date : 2021

Pages : 327

Region : United States, Japan, EU4 & UK

Summary
TOC Table of Content
LOT
Companies
- Sample Request

congestive heart failure chf market

DelveInsight’s ‘Congestive Heart Failure (CHF) - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Congestive Heart Failure, historical and forecasted epidemiology as well as the Congestive Heart Failure market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Congestive Heart Failure (CHF) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Congestive Heart Failure (CHF) market size from 2018 to 2030. The report also covers current Congestive Heart Failure (CHF) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2018–2030

Congestive Heart Failure Disease Understanding and Treatment Algorithm

Congestive Heart Failure Overview

Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is cor pulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. Some people face the problem of HF when the heart has trouble pumping enough blood to support other organs in the body. Some people have a hardening and stiffening of the heart muscle themself, which blocks or reduces blood flow towards the heart. HF initially causes the shortness of breath and fatigue (tiredness) and the right-side may further cause fluid to build up in the feet, ankles, legs, liver, abdomen, and the veins in the neck.

The body depends on the heart to pump and deliver oxygen and nutrient-rich blood to every cell. When the cells are nourished accurately, the body gains the ability to work normally. With HF, the weakened heart is not able to supply nutrients to the cells with enough blood which results in fatigue and shortness of breath and some people coughing (American Heart Association, n.d.)

HF is triggered by structural and functional limitations in the myocardium resulting in damage of ventricular filling or the ejection of blood by the heart. The most common cause for HF is lowering of the left ventricular myocardial utility along with the dysfunction of pericardium, myocardium, endocardium, heart valves or large vessels alone or in the combination. Some of the major pathogenic mechanisms leading to HF are excessive neurohumoral stimulation, irregular myocyte calcium cycling, augmented hemodynamic overload, ischemic dysfunction, ventricular remodeling, extreme or inadequate production of the extracellular matrix, enhanced apoptosis and genetic mutations.

Congestive Heart Failure Diagnosis

The assessment for HF is achieved using numerous parameters, like physical testing of the patient to know the occurrence of clinical symptoms of the HF, various blood tests, which includes complete blood count, urine analysis, serum creatinine, glucose, lipid fasting profile, metabolic profiling for serum electrolytes which includes magnesium and calcium, blood urea nitrogen, liver tests, and thyroid hormone estimation.

The diagnosis is normally measured whether a patient has a disease or condition that can cause HF in different forms like elevated blood pressure, ischemic heart problem, or diabetes. There is no single diagnostic test for the determination of the HF. If a person has signs and symptoms of HF, then the physician recommends one or more tests which will be completed through cardiologist.

Congestive Heart Failure Treatment

The available treatment can be divided into different drugs classes like angiotensin-converting enzyme inhibitors, angiotensin receptor II blockers, beta-blockers, aldosterone antagonists, amiodarone antiaggregants, anticoagulants, calcium antagonists, diuretics, nitrates, and others. The approved therapies for HF include Entresto and Corlanor, in addition to Jardince, Farxiga, and Verquvo, which are recently approved treatments for HF patients.

Lifestyle modifications, such as cessation of smoking and alcohol consumption (especially if this is thought to be the etiology), weight loss (where appropriate) and engagement in aerobic exercise, should be encouraged. Immunization against influenza (yearly) and pneumococcus is recommended. Fluid intake should be restricted to between 1.5 and 2 L/day and the patient advised of the importance of monitoring fluid balance (e.g., daily weights). Salt-rich foods should be avoided.

Congestive Heart Failure Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of HF, Diagnosed Prevalent Population of HF, Gender-specific diagnosed prevalent cases of HF, Age-specific diagnosed prevalent cases of HF, NYHA class-specific diagnosed prevalent cases of HF, Type-specific diagnosed prevalent cases of HF, Diagnosed prevalent cases of HF with Ejection Fraction, Diagnosed Prevalent cases of HF associated with comorbidities scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

Key Findings

Total Diagnosed Prevalent Cases of Heart Failure (HF) in the 7MM was found to be 12,602,028 in 2020, which is expected to grow during the study period (2018-2030).
Among 7MM, the United States has the highest diagnosed prevalent population of HF, i.e., 5,163,119 cases in 2020, which is 40.97% of the total diagnosed cases of HF in the 7MM.
In EU-5, Germany has the highest number of diagnosed cases, i.e., 2,216,497 followed by Spain with 1,283,827 cases and Italy with 1,164,031 cases. While, UK has the least number of cases with 728,547 in 2020.
There are several Heart Failure related comorbidities which include obesity, hyperlipidemia, metabolic syndrome, and others. Amongst them in the US, in 2020, 3,837,746, 2,237,179, 991,319, 1,626,382, 1,587,659, 3,097,871, and 2,065,247 cases were observed in Hypertension, Diabetes Mellitus, Chronic Kidney Disease, Atrial Fibrillation, COPD, Ischemic heart disease, and Dilated cardiomyopathy.
Age-specific diagnosed prevalent cases are seen maximum in the age group of 75–84 (1,607,918) and lowest in <44 (155,410) in 2020, this is due to the progressive aging of the population as well as improved and better survival after cardiac insults, such as myocardial infarction, especially in developed countries.
In 2020, the estimated cases of HFpEF (HFmEF) and HFrEF in the US were 3,097,871 and 2,065,247 which is expected to increase by 2030.
In 2020, New York Heart Association (NYHA) Classification is comprised of class I (No symptoms and no limitation in ordinary physical activity), class II (Mild symptoms and slight limitation during ordinary activity), class III (Marked limitation in activity due to symptoms, even during less than ordinary activity), and class IV (Severe limitations) cases which were estimated to be 2,597,106, 1,492,063, 509,236, and 509,236 cases, in the US.
In 2020, the estimated cases of acute heart failure and chronic heart failure in US were 1,548,936 and 3,614,183, respectively.
Heart failure is an important cause of morbidity and mortality in women, and the patients tend to develop it at an older age. According to the analysis, in 2020, the estimated cases of HF were 2,478,297 in males and 2,684,822 in females, in the US.

Country Wise- Congestive Heart Failure Epidemiology

The epidemiology segment also provides the Congestive Heart Failure epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Congestive Heart Failure Drug Chapters

The drug chapter segment of the Congestive Heart Failure report encloses the detailed analysis of Congestive Heart Failure mid and late stage pipeline drugs. It also helps to understand the Congestive Heart Failure clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Congestive Heart Failure Marketed Drugs

Entresto (Sacubitril and Valsartan): Novartis

Entresto combines a neprilysin inhibitor and an angiotensin II receptor blocker which reduces NT-proBNP and is expected to improve cardiovascular outcomes. Sacubitril is a neprilysin inhibitor. Valsartan, on the other hand, is an angiotensin II receptor blocker, also known as ARB. The drug keeps blood vessels from contracting and helps in decreasing the blood pressure, and progresses blood flow. The recommended starting dose of Entresto is 49/51 mg (sacubitril/valsartan) twice daily. Double the dose of Entresto after 2–4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice daily, as tolerated by the patient. In February 2021, Novartis announced that the US FDA had approved the following expanded indication for Entresto (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with CHF.